NASDAQ:EPIX
ESSA Pharma Inc. Stock News
$4.78
-0.150 (-3.04%)
At Close: Jul 03, 2024
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 30'th May 2024
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing no
ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer
05:44pm, Wednesday, 29'th May 2024
ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overco
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
07:00am, Tuesday, 14'th May 2024
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antian
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
08:00am, Tuesday, 09'th Apr 2024
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
08:13pm, Thursday, 07'th Mar 2024
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA , March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developin
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
07:00am, Tuesday, 13'th Feb 2024
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achievi
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 06'th Feb 2024
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
07:00am, Tuesday, 12'th Dec 2023
Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scien
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
08:00am, Tuesday, 21'st Nov 2023
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve
ESSA Pharma to Present at the Jefferies London Healthcare Conference
08:00am, Wednesday, 08'th Nov 2023
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on develop
ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance
07:06pm, Tuesday, 07'th Nov 2023
A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
05:51pm, Monday, 06'th Nov 2023
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel
Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
07:00am, Thursday, 31'st Aug 2023
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Aug. 31, 2023 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developi
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
07:00am, Tuesday, 08'th Aug 2023
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Ente
